FOLD: Amicus Therapeutics, Inc Company Profile & Statistics

About

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.

Info & Links

CEO

Bradley L. Campbell

Headquarters

47 Hulfish Street
Princeton, NJ 08542, UNITED STATES

Auditor

Ernst & YoungLLP

Share holders

Employees

499

Amicus Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization²

2.75B

Enterprise Value

2.92B

Enterprise Value/EBITDA(ttm)

81.89

Price to Earnings Ratio(ttm)

159.33

Price to Sales(ttm)

5.41

Price to Book(mrq)

15.97

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

89.90%

Operating Margin(ttm)

3.74%

Profit Margin(ttm)

-22.60%

Return on Equity(ttm)

13.43%

Return on Invested Capital(ttm)

-19.70%

Return on Assets(ttm)

2.63%

Income Statement

Revenue(ttm)

528.29M

Revenue Per Share(ttm)

1.76

Gross Profit(ttm)

475.35M

EBITDA(ttm)³

35.69M

Net Income Available to Common(ttm)

-56.11M

Diluted EPS(ttm)

-0.18

Share Statistics

Beta (5Y Monthly)

0.61

52-Week Change

-32.93%

S&P 500 52-Week Change

18.21%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

300.12M

Dividend Yield

0.00%

Float⁴

292.23M

% Held by Insiders

2.20%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

249.95M

Total Cash Per Share(mrq)

0.83

Total Debt(mrq)

390.11M

Total Debt/Equity(mrq)

217.81%

Current Ratio(mrq)

3.15%

Quick Ratio(mrq)

2.42%

Book Value Per Share(mrq)

0.60

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.10

Free Cash Flow(ytd)

-33.24M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FOLD

Amicus Therapeutics, Inc

Amicus Therapeutics, Inc Profile